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EDITORIALKupffer Cell TLR2/3 Signaling: A Pathway for EGCG
Amelioration of Ethanol-Induced Hepatic Injurylcoholic liver disease (ALD) affects millions of peo-Figure 1. ECGC induces IL-10 production and M2
macrophage polarization to suppress ALD development.
Alcohol-induced liver injury is mediated through TLR2 but
inhibited by TLR3 signaling. ECGC can effectively suppress
alcohol-induced liver injury by inducing IL-10 expression and
M2 polarization. The ECGC-mediated inhibitory effect on
alcohol-induced liver injury is mediated by activating TLR3
and inhibiting TLR2 in Kupffer cells.Aple worldwide and is a condition associated with
high morbidity and mortality. Ethanol-induced liver
injury encompasses acute liver injury (alcoholic hepati-
tis) and chronic liver injury (steatohepatitis, ﬁbrosis,
and cirrhosis). Currently, few therapeutic options for
ALD are available. Corticosteroids remain the gold
standard therapy for severe alcoholic hepatitis. New
research has sought to understand the role of immune
modulation, gut microbiota, caspase inhibitors, gran-
ulocyte colony–stimulating factor, interleukin (IL)-1 re-
ceptor antagonists, and farnesoid X receptor agonists in
altering the pathophysiology and halting the progression
of ALD.
The pathophysiology of ALD involves many processes
including cellular damage caused by inﬂammation and
oxidative stress and ultimately cellular death. Research
groups have proposed that polyphenol epigallocatechin-
3-gallate (EGCG) may be a promising therapy for ALD;
however, the mechanism is unclear. EGCG is a catechin
within the larger group of polyphenols and is a plant
extract found in green tea. It has already been investi-
gated because of its ability to mitigate effects of damage
caused by lead and amyloid peptides in human neuronal
cells, and having antiatherosclerotic, anti-inﬂammatory,
and antioxidant properties.1,2
In the past 2 decades, immune modulation via toll-like
receptors (TLRs) has become a topic of interest as a
therapeutic target in ALD. In addition to microbial prod-
ucts, such as lipopolysaccharide, TLRs can also recognize
endogenous molecules from damaged cells, tissues,
extracellular matrix, and danger signals, termed damage-
associated molecular patterns. In ALD, ethanol exposure
decreases the strength of gastrointestinal junctions,
leading to an increase in microbiota and endogenous
molecules seen by the liver and thus able to be presented
to TLRs. TLR2 is a receptor for gram-positive bacterial
cell wall components, such as lipoproteins, and endoge-
nous ligands, high mobility group B-1, serum amyloid A,
antiphospholipid antibodies, hyaluronan, and saturated
fatty acids. In hepatocytes, TLR2 deﬁciency has undeﬁned
effects with some studies showing TLR2 deﬁciency may
confer resistance to the effects of ethanol exposure.3
TLR3, located in the intracellular endolysosome, can
sense microbial-derived nucleic acids and double-
stranded RNA. One study has led to the proposed mech-
anism that TLR3 activation is protective in ALD as TLR3
stimulation leads to Kupffer and stellate cell activation
via enhanced production of IL-10, a liver-protective
cytokine.4CelluIn the current issue of Cellular and Molecular Gastroen-
terology and Hepatology, Luo et al5 provide additional evi-
dence that in Kupffer cells, EGCG divergently regulates IL-10
expression by interacting with TLR2 and TLR3 receptors
(Figure 1).
This study ﬁrst provided evidence that ALD injury is
decreased with EGCG. In ALD, EGCG decreased all injury and
inﬂammatory markers, such as serum aminotransferase,
tumor necrosis factor-a, IL-1b, IL-6, monocyte chemo-
attractant protein-1, and hepatic nuclear factor (NF)-kB
phosphorylation, but surprisingly showed increased anti-
inﬂammatory IL-10 levels.
The study then demonstrated that EGCG could induce IL-
10 directly from Kupffer cells. This is novel because it
incorporated the use of an in vivo model. EGCG was shown
to increase IL-10 transcription and translation. Lipopoly-
saccharide increased p38 MAPK, ERK, NF-kB p65 phos-
phorylation, whereas ECGC inhibited p38 MAPK and NF-kB
phosphorylation. In addition, EGCG decreased M1 markers,
such as inducible nitric oxide synthase, but increased M2
markers, including Arginase-1. This demonstrated that
EGCG contributes to Kupffer cell M2 polarization to protect
against ALD.lar and Molecular Gastroenterology and Hepatology 2020;9:187–188
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in TLR2-/- and TLR3-/- mice. Supplementation of EGCG in
TLR2-/- mice yielded decreased liver injury, whereas in
TLR3-/- mice, EGCG supplementation revealed increased
liver injury. EGCG was posited to work in a protective
manner in the absence of TLR2 stimulation and act to have
an opposite effect in the absence of TLR3. These experi-
ments were repeated in IL10-/- mice. EGCG supplementa-
tion had decreased protection if IL-10 was knocked out,
suggesting that IL-10 is at least one mediator in the pro-
tective effects induced by EGCG. In mice with present
TLR2/3, IL-10 production yielded liver protection. It re-
mains unknown how mechanistically EGCG interacts with
TLR2 and TLR3. Although these experiments were con-
ducted in TLR2 and TLR3 knockout Kupffer cells, the
mechanism of Kupffer cell dysfunction and its role in ALD
additionally warrants further investigation. Other key
mediators among TLR2/3, NF-kB, and IL-10 remain to be
investigated. This experiment is novel in that it demon-
strated in vivo beneﬁts of EGCG, which could be superior
to other treatments including resveratrol, silibinin,
N-Acetyl Cysteine, and prednisolone. In this manner, the
study was critical in demonstrating strong evidence for a
proposed mechanism for EGCG action. This study mark-
edly furthers the understanding of EGCG within the
context of ALD pathophysiology and provides a new area
of investigation in therapies that may beneﬁt patients
suffering from ALD.
TORREY Y. CZECH, BS
School of Medicine, University of California San Diego
La Jolla, California
EKIHIRO SEKI, MD, PhD
Division of Digestive and Liver Diseases, Department of
Medicine
Department of Biomedical Sciences
Cedars-Sinai Medical Center
Los Angeles, CaliforniaReferences
1. Ayyalasomayajula N, Ajumeera R, Chellu CS, Challa S.
Mitigative effects of epigallocatechin gallate in terms of
diminishing apoptosis and oxidative stress generated by
the combination of lead and amyloid peptides in human
neuronal cells. J Biochem Mol Toxicol 2019:e22393.
2. Eng QY, Thanikachalam PV, Ramamurthy S. Molecular
understanding of Epigallocatechin gallate (EGCG) in
cardiovascular and metabolic diseases.
J Ethnopharmacol 2018;210:296–310.
3. Roh YS, Zhang B, Loomba R, Seki E. TLR2 and TLR9
contribute to alcohol-mediated liver injury through in-
duction of CXCL1 and neutrophil inﬁltration. Am J
Physiol Gastrointest Liver Physiol 2015;309:G30–G41.
4. Byun JS, Suh YG, Yi HS, Lee YS, Jeong WI. Activation of
toll-like receptor 3 attenuates alcoholic liver injury by
stimulating Kupffer cells and stellate cells to produce
interleukin-10 in mice. J Hepatol 2013;58:342–349.
5. Luo P, Wang F, Wong N-K, Lv Y, Li X, Li M, Tipoe GL,
So K-F, Xu A, Chen S, Xiao J, Wang H. Divergent roles of
Kupffer cell TLR2/3 signaling in alcoholic liver disease
and the protective role of EGCG. Cell Mol Gastroenterol
Hepatol 2020;9:145–160.Correspondence
Address correspondence to: Ekihiro Seki, MD, PhD, Division of Digestive and
Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, 8700
Beverly Boulevard, Davis Research Building, Suite 2099, Los Angeles,
California 90048. e-mail: Ekihiro.Seki@cshs.org.
Conﬂicts of interest
The authors disclose no conﬂicts.
Funding
This work is supported by National Institutes of Health grants R01AA027036,
R01DK085252, and R21AA025841.
Most current article
© 2020 The Authors. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
2352-345X
https://doi.org/10.1016/j.jcmgh.2019.10.001
